152 related articles for article (PubMed ID: 12707458)
1. Efficacy of levetiracetam in a patient with Unverricht-Lundborg progressive myoclonic epilepsy.
Kinrions P; Ibrahim N; Murphy K; Lehesjoki AE; Järvela I; Delanty N
Neurology; 2003 Apr; 60(8):1394-5. PubMed ID: 12707458
[No Abstract] [Full Text] [Related]
2. [From gene to disease; progressive myoclonus epilepsy of Unverricht-Lundborg and mutations in the cystatin B gene].
de Haan GJ; Halley DJ; Deelen WH; Lindhout D
Ned Tijdschr Geneeskd; 2002 May; 146(18):846-8. PubMed ID: 12038222
[TBL] [Abstract][Full Text] [Related]
3. Levetiracetam in progressive myoclonic epilepsy: an exploratory study in 9 patients.
Crest C; Dupont S; Leguern E; Adam C; Baulac M
Neurology; 2004 Feb; 62(4):640-3. PubMed ID: 14981187
[TBL] [Abstract][Full Text] [Related]
4. Loss of lysosomal association of cystatin B proteins representing progressive myoclonus epilepsy, EPM1, mutations.
Alakurtti K; Weber E; Rinne R; Theil G; de Haan GJ; Lindhout D; Salmikangas P; Saukko P; Lahtinen U; Lehesjoki AE
Eur J Hum Genet; 2005 Feb; 13(2):208-15. PubMed ID: 15483648
[TBL] [Abstract][Full Text] [Related]
5. Cystatin B: mutation detection, alternative splicing and expression in progressive myclonus epilepsy of Unverricht-Lundborg type (EPM1) patients.
Joensuu T; Kuronen M; Alakurtti K; Tegelberg S; Hakala P; Aalto A; Huopaniemi L; Aula N; Michellucci R; Eriksson K; Lehesjoki AE
Eur J Hum Genet; 2007 Feb; 15(2):185-93. PubMed ID: 17003839
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the cystatin B gene promoter harboring the dodecamer repeat expanded in progressive myoclonus epilepsy, EPM1.
Alakurtti K; Virtaneva K; Joensuu T; Palvimo JJ; Lehesjoki AE
Gene; 2000 Jan; 242(1-2):65-73. PubMed ID: 10721698
[TBL] [Abstract][Full Text] [Related]
7. Clinical picture of EPM1-Unverricht-Lundborg disease.
Kälviäinen R; Khyuppenen J; Koskenkorva P; Eriksson K; Vanninen R; Mervaala E
Epilepsia; 2008 Apr; 49(4):549-56. PubMed ID: 18325013
[TBL] [Abstract][Full Text] [Related]
8. Levetiracetam in three cases of progressive myoclonus epilepsy.
Papacostas S; Kkolou E; Papathanasiou E
Pharm World Sci; 2007 Jun; 29(3):164-6. PubMed ID: 17242859
[TBL] [Abstract][Full Text] [Related]
9. [Successful treatment of epilepsy and circadian rhythm disturbance with levetiracetam in a patient with dentatorubral-pallidoluysian atrophy (DRPLA)].
Hamada S; Shimakawa S; Satomura S; Naito E; Hashimoto T
No To Hattatsu; 2014 Nov; 46(6):439-42. PubMed ID: 25558587
[TBL] [Abstract][Full Text] [Related]
10. Molecular background of progressive myoclonus epilepsy.
Lehesjoki AE
EMBO J; 2003 Jul; 22(14):3473-8. PubMed ID: 12853462
[TBL] [Abstract][Full Text] [Related]
11. Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam.
Genton P; Gelisse P
Neurology; 2001 Sep; 57(6):1144-5. PubMed ID: 11571362
[No Abstract] [Full Text] [Related]
12. The epilepsy, the protease inhibitor and the dodecamer: progressive myoclonus epilepsy, cystatin b and a 12-mer repeat expansion.
Lalioti MD; Antonarakis SE; Scott HS
Cytogenet Genome Res; 2003; 100(1-4):213-23. PubMed ID: 14526183
[TBL] [Abstract][Full Text] [Related]
13. Intramolecular i-motif structure at acidic pH for progressive myoclonus epilepsy (EPM1) repeat d(CCCCGCCCCGCG)n.
Pataskar SS; Dash D; Brahmachari SK
J Biomol Struct Dyn; 2001 Oct; 19(2):307-13. PubMed ID: 11697735
[TBL] [Abstract][Full Text] [Related]
14. Novel cystatin B mutation and diagnostic PCR assay in an Unverricht-Lundborg progressive myoclonus epilepsy patient.
Bespalova IN; Adkins S; Pranzatelli M; Burmeister M
Am J Med Genet; 1997 Sep; 74(5):467-71. PubMed ID: 9342192
[TBL] [Abstract][Full Text] [Related]
15. First Molecular Diagnosis of a Patient with Unverricht-Lundborg Disease in Korea.
Kim KH; Song JS; Park CW; Ki CS; Heo K
Yonsei Med J; 2018 Aug; 59(6):798-800. PubMed ID: 29978618
[TBL] [Abstract][Full Text] [Related]
16. Mutations in the gene encoding cystatin B in progressive myoclonus epilepsy (EPM1).
Pennacchio LA; Lehesjoki AE; Stone NE; Willour VL; Virtaneva K; Miao J; D'Amato E; Ramirez L; Faham M; Koskiniemi M; Warrington JA; Norio R; de la Chapelle A; Cox DR; Myers RM
Science; 1996 Mar; 271(5256):1731-4. PubMed ID: 8596935
[TBL] [Abstract][Full Text] [Related]
17. Generation of a human induced pluripotent stem cell line (UEFi004-A) from a patient with progressive myoclonic epilepsy type 1 (EPM1).
Singh S; Plotnikova L; Karvonen K; Ryytty S; Hyppönen J; Kälviäinen R; Hämäläinen RH
Stem Cell Res; 2023 Dec; 73():103248. PubMed ID: 37951142
[TBL] [Abstract][Full Text] [Related]
18. Amelioration of disabling myoclonus in a case of DRPLA by levetiracetam.
Kobayashi K; Takeuchi A; Oka M; Akiyama M; Ohtsuka Y
Brain Dev; 2012 May; 34(5):368-71. PubMed ID: 21889282
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of topiramate as add-on therapy in two different types of progressive myoclonic epilepsy.
Demir CF; Ozdemir HH; Müngen B
Acta Medica (Hradec Kralove); 2013; 56(1):36-8. PubMed ID: 23909054
[TBL] [Abstract][Full Text] [Related]
20. Unverricht-Lundborg disease with cystatin B gene abnormalities.
Kagitani-Shimono K; Imai K; Okamoto N; Ono J; Okada S
Pediatr Neurol; 2002 Jan; 26(1):55-60. PubMed ID: 11814737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
